Kinfo
Avalon Globocare Corp logo

Avalon Globocare Corp

ALBTNASDAQReal Estate·US · USD
$0.28
-0.00 (-0.41%)
Prices as of July 13, 2026 · live

Price

Key statistics

Valuation
Market cap3.65M USD
Enterprise value30.81M USD
Trailing P/E-0.05
Forward P/E0.00
PEG ratio0.00
Price / sales0.00
Price / book0.21
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-39.69%
Return on equity-501.20%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-7.87M USD
Net income-19.63M USD
Diluted EPS-$4.52
Rev. growth (YoY)-100.00%
Balance sheet
Total cash776.00K USD
Total debt1.42M USD
Debt / equity12.10
Current ratio0.38
Book value / share-$1.81
Cash flow (TTM)
Operating cash flow-6.18M USD
Levered free cash flow-1.59M USD
Shares & price
Shares outstanding8.32M
Float10.78M
Held by institutions4.55%
Beta-0.03
50-day MA$0.35
200-day MA$1.04
52-week high$4.74
52-week low$0.21
Dividends
Forward rate
$1.04
Yield
380.95%
Payout ratio
0.00%
Frequency
Quarterly
Recent payments
  • 2022-11-18$39.00
Earnings (EPS)
DateEst.ActualSurprise2026-02-112.082.10+0.96%2025-10-200.620.65+4.84%2023-05-21-0.28
About Avalon Globocare Corp

Avalon GloboCare Corp. is a commercial-stage company focused on developing and delivering precision diagnostic consumer products, advancing cellular therapy intellectual property, and owning commercial real estate properties in the United States. It markets the KetoAir™ breathalyzer, a handheld nanosensor device that measures breath acetone levels to monitor ketosis and fat metabolism, integrated into wellness programs for first responders and ketogenic health management. The company distributes KetoAir™ through wholesale agreements, affiliate programs, and online channels in the United States and United Kingdom, while co-developing additional applications like a cannabis breathalyzer for point-of-care detection. Avalon GloboCare Corp. advances proprietary CAR-T and CAR-NK cell technologies, including bispecific designs and cytokine induction methods protected by patents in multiple jurisdictions. Through subsidiaries like Avalon Quantum AI, LLC and Q&A Distribution, LLC, it operates generative AI software for nutrition and publishing, alongside real estate operations. Founded in 2015 and headquartered in Freehold, New Jersey, Avalon GloboCare Corp. plays a role in the intersection of diagnostics, biotech IP, AI-enabled health tools, and property management within healthcare and real estate markets.

Sector
Real Estate
Industry
Real Estate Services
CEO
Ms. Meng Li
Employees
2
Headquarters
Freehold, NJ, United States

Frequently asked questions about Avalon Globocare Corp